Broadcom Q2 FY2026: Why a Blowout Report Still Sent the Stock Down 10%

Broadcom Q2 FY2026: Why a Blowout Report Still Sent the Stock Down 10%

Broadcom just delivered another strong earnings report for Q2 fiscal 2026, and the stock fell more than ten percent. CSI breaks down exactly why that happened, what it means for long-term holders, and whether anything has actually changed in the fundamental thesis for one of the most important companies in AI infrastructure.


Broadcom has compounded its enterprise value at over fifty percent annually for five years. AI semiconductors now represent roughly three-quarters of the semiconductor solutions segment, which itself makes up the majority of nearly forty-eight billion in trailing twelve-month revenue. Free cash flow hit a record dollar amount this quarter at a forty-six percent margin, still climbing toward its near-fifty percent record high.


So why did the stock sell off? The short answer is that Wall Street wanted a raise in 2027 guidance, specifically whether Broadcom's forecast of over one hundred billion in AI semiconductor revenue for fiscal 2027 would be revised higher toward two hundred billion. CEO Hock Tan declined to update that number, and without a concrete revision, earnings expectations stayed flat.

Infrastructure software, the VMware segment, is now a cash cow with sub-ten percent growth. The growth engine going forward is AI semiconductors and networking. Chip Stock Investor's position is unchanged, continuing to hold Broadcom as a core AI data center infrastructure name.


For in-depth stock research and the Semiconductor Insider membership, visit chipstockinvestor.com. Use fiscal.ai/csi for 15% off any paid plan.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(492)

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's st...

17 Syys 14min

The Fastest-Growing Chip Stock Is Also the Most Hated

The Fastest-Growing Chip Stock Is Also the Most Hated

We compare Credo (CRDO) against Broadcom (AVGO), Marvell (MRVL), and Astera Labs (ALAB) on revenue growth, gross margin, operating margin, and free cash flow margin — four fabless companies selling in...

15 Syys 13min

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

We break down the takeaways from Oracle's (ORCL) Q1 fiscal 2027 earnings call — what to expect through 2026 and into 2027–2028 as hyperscaler CapEx stays high but is set to slow in growth by 2027, and...

14 Syys 12min

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans.Nvidia has announced plans to acquire Hugging Face, the...

10 Syys 15min

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on.Pure Storage has officially rebranded as Everpure...

10 Syys 19min

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio?Procept (PRCT) has one of the mo...

10 Syys 28min

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.Oscar Health (OSCR) just posted stro...

10 Syys 11min

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — ...

2 Syys 14min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
rss-rahapodi
psykopodiaa-podcast
mimmit-sijoittaa
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
oppimisen-psykologia
rss-sami-miettinen-neuvottelija
rss-paasipodi
lakicast
rss-karon-grilli
rss-rahamania
rss-inderes
rahapuhetta
rss-siksi-viestinta
rss-pinnan-alle
rss-startup-ministerio
pomojen-suusta
inderespodi